AlphAIalphai — Financial news for AI agents
MarketBeatFEB 212 min read$HAE

Isthmus Partners LLC Acquires 16,505 Shares of Haemonetics Corporation $HAE

Isthmus Partners LLC increased its stake in Haemonetics Corporation (NYSE:HAE) by 36.5% during the third quarter, acquiring an additional 16,505 shares and bringing its total holding to 61,702 shares valued at approximately $3.01 million. Haemonetics recently surpassed analyst expectations for its quarterly earnings and revenue, while setting optimistic FY2026 guidance. Institutional investors own a significant 99.67% of the stock, which currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $84.44.

Original reporting
MarketBeat · MarketBeat
Published Feb 21, 2026, 12:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 21, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Isthmus Partners LLC Acquires 16,505 Shares of Haemonetics Corporation $HAE — source image
Source · MarketBeat
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The combination of fundamental strength and institutional support suggests a bullish outlook, which may translate into upward stock price movement.

02

Market read

The news is highly relevant for investors interested in healthcare and medical device sectors, especially those focusing on institutional investment trends.

03

What to watch

Market-wide corrections or sector-specific downturns could negate positive company fundamentals.

Timing: Immediate; news published within the last 24 hours.

Background

Haemonetics Corporation has recently reported better-than-expected earnings and revenue, with strong analyst guidance for FY2026. Institutional investors have increased their holdings, indicating confidence in the company's prospects.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Significant institutional buying and positive earnings guidance suggest bullish sentiment.

Expected impact

Moderate to significant upward price movement in the short to medium term.

Evidence & confidence

The combination of increased institutional ownership, surpassing earnings expectations, and optimistic guidance provides a strong fundamental basis for bullish momentum.

Market effects

Sector

Positive sentiment may bolster the medical devices and life sciences sector.

Regional

Primarily US-focused due to the company's listing and investor base.

Global

Moderate; sector performance can influence global healthcare markets.

Counterpoint

What could challenge this read

The high institutional ownership could lead to profit-taking if short-term gains are realized, potentially causing a temporary dip.

Key entities

  • Company
    Haemonetics Corporation

    A global healthcare company specializing in blood management solutions.

  • Institutional Investor
    Isthmus Partners LLC

    An investment firm increasing its stake in HAE.

Read at source← All news

Related articles

AUG 9
$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.

yahoo.com6 min
AUG 6
$HAEMed

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations

Haemonetics (NYSE:HAE) reported Q2 CY2026 results. Revenue rose 5.6% year on year to $339.4 million, exceeding Wall Street estimates by 2.8%. Non-GAAP adjusted EPS was $1.14, up from $1.10 and 5.8% above consensus. Analysts expect revenue growth of about 5% over the next 12 months and full-year EPS to rise from $5.01 to $5.36.

financialcontent.com6 min
AUG 6
$HAEHigh

HAEMONETICS CORP (HAE): Results of Operations and Financial Condition

HAEMONETICS CORP (HAE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-fy27q1earningsrelease.htm EX-99.1 Document Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.git

SEC EDGAR 8-K4 min
AUG 9
$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

dailysabah.com6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min